Answers are grounded in this paper and cite their sources.
Background The therapeutic landscape of breast cancer is undergoing a transformative shift toward targeted, biomarker-driven, and toxicity-sparing therapies. Despite these breakthroughs across molecular subtypes, managing a visceral crisis remains a formidable clinical challenge that presents severe decision-making dilemmas for oncologists and an overwhelming burden for patients. In particular, treating aggressive breast cancer with bone marrow metastasis (BMM) is complicated by severe cytopenias and a history of trastuzumab-induced cardiotoxicity, creating a delicate balance between anti-neoplastic efficacy and life-threatening toxicity. Case description A 39-year-old female with HER2-positive early breast cancer developed severe left ventricular dysfunction with an ejection fraction (EF) of 35% during adjuvant trastuzumab-pertuzumab regimen, which fully recovered to 55% following treatment discontinuation. Six months later, she presented with an L4–L5 osseous metastasis causing spinal cord compression. First-line metastatic trastuzumab emtansine (T-DM1) was initiated. After 4 cycles, she developed severe, persistent pancytopenia. A diagnostic bone marrow biopsy confirmed active carcinoma infiltration. Due to disease progression and bone marrow failure, she was transitioned to trastuzumab deruxtecan (T-DXd). T-DXd cleared the marrow microenvironment, restored hematopoiesis, and achieved disease control without recurrent cardiotoxicity. Conclusion T-DXd can serve as a potent salvage therapy to clear the bone marrow microenvironment and reverse malignant cytopenias without exacerbating baseline hematological toxicity, even in patients with a history of transient trastuzumab-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Karakeci et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: